Study S000906

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

ClinicalTrials.gov record

Registration

Registration: NCT07481747
Acronym: SURMOUNT-1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: RECRUITING
Enrollment: 2539
Start: 2026-02-02
Primary completion: 2027-02-14
Lead sponsor: Hudson Biotech
Conditions: Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Interventions: DRUG:Tirzepatide; DRUG:Placebo; BEHAVIORAL:Reduced-calorie diet
Results posted: FALSE

Registered primary outcomes

Mean percent change in body weight from randomization [72 Weeks]
Percentage of participants achieving ≥5% body weight reduction from randomization [72 Weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.